Lou, E., Reardon, D. A., Peters, K., Desjardins, A., Herndon, J. E., Coan, A. D., … Vredenburgh, J. J. (2011). Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology, 29(15_suppl), 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055

Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055.

Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):2055–2055.

Lou, E., et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. 2055–2055. Crossref, doi:10.1200/jco.2011.29.15_suppl.2055.

Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, Turner SG, Sumrall AL, Bailey L, Friedman HS, Vredenburgh JJ. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):2055–2055.